Image MCQ: Peripheral Blood Smear for NEET PG (AML M3 Auer Rods, CML, ALL, ITP, HUS/TTP)

Version 1.0 — Published May 2026

Why peripheral smear image MCQs are high-yield for NEET PG

Peripheral blood smear is the cheapest, fastest, and most diagnostic test in haematology — accessible in every primary health centre across India, often the first investigation that changes the diagnosis from "anaemia" to "leukaemia" or from "fever" to "malaria". NEET PG, INI-CET, and FMGE feature peripheral smear images in 4-6 questions per paper, often coupled with a clinical vignette to test the whole diagnostic chain — pattern recognition, additional confirmatory tests, and management.

The patterns are highly stereotyped. Drilling 5 patterns plus 5-10 PYQ smear images daily for 2 weeks moves accuracy from 40 to 80 percent on this high-yield domain.

Foundational approach before the MCQs

Four-line systematic smear analysis

Age-based leukaemia shortlists

MCQ 1: 28-year-old woman with bruising, gum bleeding, and circulating blasts

Image description: [High-power (x1000) Wright-Giemsa stained peripheral blood smear of a 28-year-old woman. Multiple promyelocytes are visible — large cells with abundant granular cytoplasm, an indented or bilobed nucleus, and prominent bundles of needle-shaped Auer rods stacked together (faggot cells). Several promyelocytes contain dozens of Auer rods aggregated in the cytoplasm. There is hypergranular cytoplasm with intense azurophilic granulation. Background red cells appear normal. Platelets are markedly decreased on the smear. WBC count on automated counter is 2,400/μL — leukopenia rather than leukocytosis (the classic 'hypergranular hypocellular' variant of APL).]

Clinical vignette: A 28-year-old previously healthy woman presents with 1 week of progressive fatigue, easy bruising over the arms and thighs, bleeding gums on brushing, and a small epistaxis the previous evening. No fever, no weight loss, no infection. On examination she is pale; multiple ecchymoses on the limbs and trunk; no lymphadenopathy; no hepatosplenomegaly. Labs: Hb 8.2 g/dL, WBC 2,400/μL (neutrophils 35 percent, promyelocytes 45 percent on differential), platelets 18,000/μL. Coagulation: PT 22 sec (raised), aPTT 52 sec (raised), INR 2.0, fibrinogen 0.9 g/L (low), D-dimer markedly raised — overt DIC. Bone marrow aspirate confirms over 80 percent promyelocytes with faggot cells.

Options:

• (a) Acute promyelocytic leukaemia (AML M3) with DIC
• (b) Acute myelomonocytic leukaemia (AML M4)
• (c) Chronic myeloid leukaemia in blast crisis
• (d) Acute lymphoblastic leukaemia (ALL)

Correct answer: (a) Acute promyelocytic leukaemia (AML M3) with DIC

Reasoning: Young adult with leukopenia or modestly raised WBC, dominance of promyelocytes with bundles of Auer rods (faggot cells), and prominent coagulopathy with overt DIC at presentation is textbook acute promyelocytic leukaemia (APL, AML M3). The cytogenetic hallmark is t(15;17)(q24;q21) producing the PML-RARA fusion gene — confirmed by FISH or PCR. The hypergranular cytoplasm and the bundles of Auer rods discriminate from other AML subtypes.

AML M4 (acute myelomonocytic) produces a mix of myeloblasts and monoblasts with non-specific esterase positivity and gingival hyperplasia — no faggot cells. CML in blast crisis produces a high WBC with a full granulocyte maturation spectrum plus blasts; M3 is leukopenic in 70 percent of cases. ALL produces lymphoblasts without granules or Auer rods, often TdT positive on immunohistochemistry — never faggot cells.

Teaching pearl: APL key features — promyelocytes with faggot cells (bundles of Auer rods), DIC at presentation in 80-90 percent of cases, t(15;17) PML-RARA fusion, leukopenia rather than leukocytosis in 70 percent (hypergranular variant). The hypogranular variant (M3v) has a bilobed/folded nucleus, scant granules, higher WBC, and similar Auer rods on careful examination.

Critical management point — the ATRA emergency:

• Suspect APL → start ATRA (all-trans retinoic acid) IMMEDIATELY before cytogenetic confirmation; delay kills patients through DIC
• Combine with arsenic trioxide (ATO) for standard-risk APL (no chemotherapy in many protocols) or ATRA + ATO + idarubicin for high-risk APL (WBC over 10,000)
• Aggressive DIC support — platelets to keep over 30,000-50,000, fibrinogen to keep over 1.5 g/L (cryoprecipitate, FFP), maintain Hb over 8
• Differentiation syndrome (ATRA syndrome) — fever, dyspnoea, weight gain, pleural effusion, hypotension within first 21 days of ATRA; treat with dexamethasone 10 mg q12h
• Cure rate over 90 percent with modern ATRA + ATO — APL has moved from the most lethal to one of the most curable adult leukaemias

Differentiator vs other AML subtypes (FAB classification):

MCQ 2: 45-year-old man with massive splenomegaly and a very high WBC count

Image description: [High-power Wright-Giemsa peripheral blood smear of a 45-year-old man. There is marked leukocytosis with a full spectrum of granulocyte maturation — myeloblasts (rare, around 2 percent), promyelocytes, myelocytes, metamyelocytes, band forms, and mature neutrophils — all present simultaneously. Basophilia is prominent (15 percent basophils on differential), with eosinophilia (8 percent) also visible. Platelets are increased. Red cells appear normal in number and morphology. No Auer rods are seen in the rare blasts present. The picture is sometimes described as 'all stages of the marrow are in the blood'.]

Clinical vignette: A 45-year-old businessman from Pune presents with 3 months of progressive abdominal fullness, early satiety, weight loss of 4 kg, night sweats, and fatigue. On examination there is massive splenomegaly extending to the umbilicus and beyond into the left iliac fossa, mild hepatomegaly 3 cm below costal margin, and no lymphadenopathy. Labs: Hb 11.2 g/dL, WBC 156,000/μL with the differential described above, platelets 480,000/μL, LDH 1,840 U/L, uric acid 8.4 mg/dL, leukocyte alkaline phosphatase (LAP) score very low (4 — normal 20-100). Bone marrow aspirate shows hypercellular marrow with myeloid hyperplasia and decreased M:E ratio reversed. Cytogenetics show t(9;22)(q34;q11) — Philadelphia chromosome producing the BCR-ABL fusion gene on FISH and PCR.

Options:

• (a) Leukemoid reaction to severe infection
• (b) Chronic myeloid leukaemia (CML) in chronic phase
• (c) Polycythemia vera
• (d) Myelofibrosis (primary myelofibrosis)

Correct answer: (b) Chronic myeloid leukaemia (CML) in chronic phase

Reasoning: Middle-aged adult with massive splenomegaly, WBC over 100,000 with full granulocyte maturation spectrum and prominent basophilia + eosinophilia, low LAP score, and t(9;22) Philadelphia chromosome on cytogenetics is textbook CML in chronic phase. The basophilia is a particularly useful discriminator because it is rarely present in leukemoid reactions.

Leukemoid reaction to infection produces a left shift but typically has fewer immature forms, no basophilia, high LAP score (over 100 — opposite to CML), and a clear inflammatory context. Polycythemia vera presents with raised red-cell mass and JAK2 V617F mutation; the WBC and platelet rise are usually modest. Primary myelofibrosis produces a leukoerythroblastic picture with teardrop cells and bone marrow fibrosis on biopsy, JAK2 or CALR mutations.

Teaching pearl: CML key features — middle-aged adult, massive splenomegaly, full granulocyte maturation in the blood, basophilia + eosinophilia, low LAP score, t(9;22) BCR-ABL Philadelphia chromosome, three phases (chronic → accelerated → blast crisis). Distinguish from leukemoid reaction with the low LAP score + basophilia + BCR-ABL.

Phases of CML:

Management:

• First-line: imatinib (Gleevec) 400 mg/day — selective BCR-ABL tyrosine kinase inhibitor; revolutionised CML; 10-year survival now over 85 percent
• Second-generation TKIs (dasatinib, nilotinib, bosutinib) — first-line in higher-risk disease or second-line for imatinib resistance
• Third-generation TKI (ponatinib) — for T315I mutation (resistant to first/second-generation)
• Allogeneic stem cell transplant — reserved for accelerated/blast crisis or TKI failure; the only curative option
• Monitor with BCR-ABL PCR for molecular response (MR4.5 = 0.0032 percent, MR4 = 0.01 percent — deep molecular response)

India-specific note: Generic imatinib (Gleevec) is widely available at affordable cost via state TKI programmes and CHAI/Patient Assistance schemes; access has improved 10-year survival in India to approach Western outcomes. Tata Memorial, AIIMS, and CMC Vellore run high-volume CML clinics.

MCQ 3: 4-year-old boy with fever, bone pain, lymphadenopathy, and circulating lymphoblasts

Image description: [High-power Wright-Giemsa peripheral blood smear of a 4-year-old boy. There are numerous small to medium-sized lymphoblasts with scant cytoplasm, condensed nuclear chromatin, and inconspicuous nucleoli (FAB L1 morphology). No Auer rods, no granules in the cytoplasm. Background red cells show mild normocytic anaemia. Platelets are decreased. On flow cytometry (described in vignette) the blasts are TdT positive, CD10 positive (CALLA), CD19 positive, CD22 positive, CD79a positive, MPO negative, surface immunoglobulin negative — common B-cell ALL.]

Clinical vignette: A 4-year-old boy presents with 2 weeks of progressive fatigue, intermittent fever, and complaints of leg pain (he often asks to be carried instead of walking). His mother noticed bruising over the shins and a few petechiae on the trunk. On examination he is pale, has bilateral cervical lymphadenopathy (1-2 cm, firm, non-tender), hepatosplenomegaly (liver 4 cm, spleen 6 cm below costal margin), and ecchymoses on both shins. Labs: Hb 6.8 g/dL, WBC 38,000/μL with 65 percent lymphoblasts on differential, platelets 28,000/μL, LDH 1,420 U/L, uric acid 9.2 mg/dL. Bone marrow aspirate shows 90 percent lymphoblasts replacing normal marrow. Flow cytometry confirms B-cell ALL. Cytogenetics show hyperdiploidy (over 50 chromosomes) — favourable prognosis. CSF cytology shows no leukaemic involvement.

Options:

• (a) Acute lymphoblastic leukaemia (B-cell ALL)
• (b) Acute myeloid leukaemia (AML M2)
• (c) Burkitt lymphoma with leukaemic phase
• (d) Infectious mononucleosis with reactive lymphocytosis

Correct answer: (a) Acute lymphoblastic leukaemia (B-cell ALL)

Reasoning: Paediatric peak age 2-5 years, fever + bone pain + lymphadenopathy + hepatosplenomegaly + pancytopenia, circulating small lymphoblasts with scant cytoplasm and no Auer rods, and immunophenotype TdT positive + CD10 + CD19 + CD22 + MPO negative is textbook B-cell ALL. Hyperdiploidy carries a favourable prognosis.

AML M2 produces myeloblasts with Auer rods, MPO positive on cytochemistry — different morphology. Burkitt lymphoma produces medium-sized to large blasts with deep blue cytoplasm and vacuoles (starry sky on biopsy), c-myc translocation t(8;14), and FAB L3 morphology. Infectious mononucleosis produces atypical (Downey) lymphocytes with abundant cytoplasm hugging surrounding red cells, not blast cells, and a positive monospot/EBV serology.

Teaching pearl: B-cell ALL key features — paediatric peak 2-5 years, lymphoblasts with scant cytoplasm and condensed chromatin, TdT positive (the discriminator from AML and lymphoma), CD10 positive (CALLA-positive), PAS positive in block pattern, MPO negative. Hyperdiploidy and ETV6-RUNX1 t(12;21) are favourable; Philadelphia chromosome t(9;22) and MLL/KMT2A rearrangement are unfavourable.

Differentiator vs AML:

Management of paediatric B-cell ALL:

• Induction: vincristine + prednisolone/dexamethasone + L-asparaginase + daunorubicin (for higher risk) — over 95 percent CR
• Consolidation/intensification: high-dose methotrexate, cytarabine
• CNS prophylaxis: intrathecal methotrexate (+ cytarabine + hydrocortisone = triple intrathecal) at multiple time points
• Maintenance: oral mercaptopurine + weekly methotrexate for 2-3 years
• Risk-adapted intensity based on age, WBC at diagnosis, cytogenetics, MRD response
• Modern paediatric ALL cure rate over 90 percent at high-volume centres — one of the great success stories of oncology
• Indian Childhood Collaborative Leukaemia Group (ICiCLe) protocol is followed widely in India

MCQ 4: 19-year-old woman with isolated thrombocytopenia and easy bruising

Image description: [High-power Wright-Giemsa peripheral blood smear of a 19-year-old woman. The platelet count is markedly decreased — only 1-2 platelets per oil-immersion field. Several megathrombocytes (giant platelets) larger than the surrounding red cells are visible — easily identified by their size (over 4 micrometres, larger than a typical 7-micrometre RBC). Red cells are normal in size, shape, and number. White cells are normal in count and morphology. No schistocytes, no spherocytes, no blasts, no immature granulocytes. The picture is otherwise unremarkable except for the isolated thrombocytopenia with megathrombocytes.]

Clinical vignette: A 19-year-old college student presents with 1 week of easy bruising on the arms and legs and bleeding gums while brushing her teeth. She had a flu-like illness 2 weeks ago that resolved spontaneously. She is otherwise well, not on any medication, no family history of bleeding disorders. On examination: vital signs normal, multiple petechiae on the legs and trunk, ecchymoses on the arms, no lymphadenopathy, no hepatosplenomegaly, no joint swelling, no rash other than petechiae. Labs: Hb 13.2 g/dL (normal), WBC 6,800/μL (normal differential), platelets 8,000/μL (severe thrombocytopenia). LFT, RFT, coagulation (PT, aPTT, fibrinogen) all normal. ANA negative. HIV, HBV, HCV negative. Bone marrow aspirate (done for severe thrombocytopenia): increased number of megakaryocytes, otherwise normal marrow.

Options:

• (a) Immune thrombocytopenia (ITP)
• (b) Thrombotic thrombocytopenic purpura (TTP)
• (c) Aplastic anaemia
• (d) Acute leukaemia
• (e) Disseminated intravascular coagulation

Correct answer: (a) Immune thrombocytopenia (ITP)

Reasoning: Young adult with isolated severe thrombocytopenia, megathrombocytes on smear, no anaemia or leukopenia, no schistocytes, no blasts, normal coagulation, increased marrow megakaryocytes, recent viral illness, and otherwise normal examination and labs is textbook immune thrombocytopenia (ITP, formerly idiopathic thrombocytopenic purpura). The post-viral history and isolated thrombocytopenia with megathrombocytes are highly characteristic.

TTP shows schistocytes (MAHA), thrombocytopenia, neurological symptoms, renal involvement, and very low ADAMTS13 activity — not isolated thrombocytopenia. Aplastic anaemia produces pancytopenia with hypocellular marrow — not increased megakaryocytes. Acute leukaemia would have blasts on smear or in marrow. DIC has prolonged coagulation with low fibrinogen and raised D-dimer — coagulation is normal in ITP.

Teaching pearl: ITP key features — isolated thrombocytopenia (Hb and WBC normal), megathrombocytes on smear (giant platelets reflecting accelerated turnover), increased megakaryocytes in marrow, normal coagulation, often post-viral (especially in children), antiplatelet antibodies (GP IIb/IIIa, GP Ib/IX), diagnosis of exclusion — rule out drug-induced thrombocytopenia, HIV, HCV, SLE, lymphoproliferative disorders.

Pathophysiology:

• Autoantibodies (IgG) against platelet surface glycoproteins (GP IIb/IIIa, Ib/IX)
• Antibody-coated platelets cleared by splenic macrophages
• Compensatory megakaryocyte hyperplasia produces large young platelets (megathrombocytes)
• In children: often post-viral (especially after EBV, varicella, measles, rubella), self-limiting in 70-80 percent
• In adults: often chronic, idiopathic, occasionally associated with H. pylori, HIV, HCV, SLE, lymphoma

Management:

• Platelet count over 30,000 and no bleeding: observation
• Platelet count under 30,000 or significant bleeding:
  • First-line: prednisolone 1 mg/kg/day for 2-4 weeks then taper; alternative is dexamethasone 40 mg/day for 4 days pulse
  • IVIG 1 g/kg for 1-2 days — rapid response; useful for urgent bleeding, before procedures, in pregnancy
  • Anti-D immunoglobulin in Rh-positive non-splenectomised patients (cheaper than IVIG)
• Refractory/chronic ITP:
  • Splenectomy — durable remission in 60-70 percent; vaccinate against encapsulated organisms (pneumococcus, meningococcus, Hib) at least 2 weeks before surgery
  • Rituximab (anti-CD20) — for refractory cases
  • Thrombopoietin receptor agonists — romiplostim (SC weekly), eltrombopag (oral daily); increasingly used as steroid-sparing agents
  • Fostamatinib — SYK inhibitor for chronic refractory ITP

ITP in pregnancy: A NEET PG favourite — distinguish from gestational thrombocytopenia (mild, late, no treatment needed) and HELLP/preeclampsia (MAHA, raised LFTs, hypertension). Treat ITP in pregnancy with prednisolone or IVIG; avoid splenectomy in pregnancy if possible.

MCQ 5: 6-year-old girl with bloody diarrhoea, anuria, and red-cell fragments

Image description: [High-power Wright-Giemsa peripheral blood smear of a 6-year-old girl. The dominant abnormality is numerous schistocytes — fragmented red cells, helmet cells, triangular fragments, and small triangular and crescent-shaped fragments — accounting for over 5 percent of red cells. Background red cells show polychromasia (reticulocytosis from compensatory marrow response). Platelets are markedly decreased. White cells are normal in number and morphology. No spherocytes, no target cells, no parasites. The combined picture is microangiopathic hemolytic anaemia (MAHA) + thrombocytopenia.]

Clinical vignette: A 6-year-old girl from Bengaluru is brought by her parents with 1 week of bloody diarrhoea that started after a family barbecue (undercooked beef burger reported), followed by 3 days of pallor, decreased urine output, dark urine, and lethargy. Today she has had no urine output for 18 hours. On examination she is pale, mildly oedematous, mildly hypertensive (BP 124/82 — over 95th centile for age), abdomen mildly distended, no rashes, no hepatosplenomegaly. Labs: Hb 6.4 g/dL, WBC 14,000/μL (mild leukocytosis with normal differential), platelets 28,000/μL, reticulocyte count 8 percent, LDH 1,800 U/L, indirect bilirubin 3.2 mg/dL, haptoglobin undetectable, direct Coombs test NEGATIVE (this is the key — DAT-negative hemolysis), creatinine 4.8 mg/dL (markedly raised), BUN 92, urinalysis shows haematuria and proteinuria. Stool culture grows E. coli O157:H7 producing Shiga-like toxin (Stx-1 and Stx-2) confirmed by PCR. ADAMTS13 activity is 65 percent (normal).

Options:

• (a) Hemolytic uraemic syndrome (HUS) — typical, Shiga-toxin-mediated
• (b) Thrombotic thrombocytopenic purpura (TTP)
• (c) Disseminated intravascular coagulation (DIC)
• (d) Autoimmune hemolytic anaemia (AIHA) with renal failure

Correct answer: (a) Hemolytic uraemic syndrome (HUS) — typical, Shiga-toxin-mediated

Reasoning: Child with prodromal bloody diarrhoea following undercooked-beef exposure, classic triad of MAHA (schistocytes, raised LDH, low haptoglobin, indirect hyperbilirubinaemia, DAT-negative) + thrombocytopenia + acute kidney injury, and stool culture growing E. coli O157:H7 with Shiga toxin is textbook typical (post-diarrhoeal, D+) HUS — also called Shiga-toxin-associated HUS or STEC-HUS. The normal ADAMTS13 activity excludes TTP.

TTP shows MAHA + thrombocytopenia + neurological symptoms + renal involvement + fever (classic pentad — full pentad is rare and the modern dyad of MAHA + thrombocytopenia alone is enough to start plasma exchange), and is caused by very low ADAMTS13 (under 10 percent) from autoantibody (acquired) or genetic deficiency (Upshaw-Schulman syndrome). In children, HUS is far more common than TTP. DIC shows prolonged PT/aPTT, low fibrinogen, raised D-dimer — not present in HUS. AIHA shows positive direct Coombs test — DAT is negative in HUS.

Teaching pearl: Typical HUS (STEC-HUS) key features — children 1-10 years, prodromal bloody diarrhoea (E. coli O157:H7 from undercooked beef, unpasteurised milk, contaminated water; less commonly Shigella dysenteriae type 1 in India), MAHA + thrombocytopenia + AKI, DAT-negative hemolysis, normal coagulation, normal ADAMTS13 (the discriminator from TTP). Treatment is supportive — fluid management, dialysis if needed, transfusion if needed, avoid antibiotics (paradoxically increase toxin release in some studies). Self-limiting in 90 percent over 2-3 weeks.

Atypical HUS (aHUS): Complement dysregulation (factor H, factor I, MCP/CD46, factor B, C3 mutations); no diarrhoeal prodrome; chronic relapsing course; treatment with eculizumab (anti-C5 monoclonal antibody).

TTP: MAHA + thrombocytopenia + neurological symptoms + renal involvement + fever (pentad); ADAMTS13 activity under 10 percent; treatment with urgent plasma exchange (PLEX) + steroids + rituximab + caplacizumab. Adults more often than children.

Differentiator vs other causes of MAHA:

HUS management:

• Supportive care: fluid and electrolyte balance, dialysis if anuria/severe AKI (continuous renal replacement therapy or peritoneal dialysis in children)
• Transfusion of red cells if Hb under 7 g/dL or symptomatic
• Avoid platelet transfusion unless active bleeding (fuels thrombotic microangiopathy)
• Antibiotics generally avoided in STEC-HUS (some studies show increased toxin release)
• Eculizumab in atypical HUS or severe/refractory STEC-HUS with CNS involvement
• No plasma exchange routinely in STEC-HUS (effective in TTP, not typical HUS)
• Outcome: 90 percent recovery in typical HUS; 5-10 percent develop chronic kidney disease or end up on long-term dialysis; mortality 3-5 percent

Common pitfalls and how to avoid them

Pitfall 1: Confusing AML M3 with M2. Both have Auer rods, but M3 has bundles of Auer rods (faggot cells), DIC at presentation, t(15;17) PML-RARA, and treated with ATRA + ATO. M2 has single Auer rods, t(8;21) RUNX1-RUNX1T1, and treated with conventional chemotherapy. Missing M3 is life-threatening because of the DIC.

Pitfall 2: Calling every left-shifted leukocytosis 'leukaemia'. Leukemoid reaction to severe infection produces a left shift but typically has higher LAP score, no basophilia, no BCR-ABL, and a clear inflammatory context. CML has low LAP score, basophilia + eosinophilia, BCR-ABL Philadelphia chromosome, and massive splenomegaly.

Pitfall 3: Confusing ALL with AML. Both have circulating blasts, but ALL is TdT positive, MPO negative, smaller cells with scant cytoplasm, no Auer rods, while AML is TdT negative, MPO positive, larger cells with more cytoplasm, may have Auer rods. ALL peaks in children 2-5; AML increases with age.

Pitfall 4: Calling all thrombocytopenia 'ITP'. ITP is isolated thrombocytopenia (Hb and WBC normal) with megathrombocytes, normal coagulation, increased marrow megakaryocytes. Thrombocytopenia with anaemia and schistocytes is MAHA (TTP, HUS, DIC). Thrombocytopenia with leukopenia is bone marrow problem (aplastic anaemia, leukaemia). Thrombocytopenia with prolonged coagulation is DIC.

Pitfall 5: Confusing TTP and HUS. Both produce MAHA + thrombocytopenia. TTP: adult, dominant neurological symptoms, ADAMTS13 under 10 percent, treat with plasma exchange. HUS: child with prodromal bloody diarrhoea, dominant renal involvement, normal ADAMTS13, E. coli O157:H7 toxin, treat supportively. Atypical HUS: complement dysregulation, treat with eculizumab.

Pitfall 6: Missing inherited macrothrombocytopenias. Bernard-Soulier (absent GP Ib/IX/V, giant platelets, family history), May-Hegglin (giant platelets + Dohle-like neutrophil inclusions, autosomal dominant), Wiskott-Aldrich (small platelets, eczema, immunodeficiency, X-linked). Family history and red-cell normality with chronic thrombocytopenia should prompt consideration.

Pitfall 7: Calling a peripheral atypical lymphocyte a 'blast'. Atypical (Downey) lymphocytes in infectious mononucleosis have abundant cytoplasm hugging surrounding red cells, mature chromatin, no Auer rods, no granules — they are reactive T-cells responding to EBV. They are NOT blasts.

How NEET PG tests peripheral blood smear

Seven recurring patterns. Recognise the pattern and the question collapses to a 30-second answer.

Pattern 1 — The faggot cell question: Smear shows promyelocyte with bundles of Auer rods + young adult with bleeding and DIC. Diagnosis? APL (AML M3). Cytogenetics? t(15;17) PML-RARA. First-line treatment? ATRA + arsenic trioxide; start ATRA empirically before cytogenetic confirmation because DIC is life-threatening.

Pattern 2 — The CML question: Smear shows full granulocyte maturation spectrum + basophilia + middle-aged adult with massive splenomegaly + WBC over 100,000 + low LAP score. Diagnosis? CML chronic phase. Cytogenetics? t(9;22) BCR-ABL Philadelphia chromosome. Treatment? Imatinib (or dasatinib/nilotinib).

Pattern 3 — The ALL question: Smear shows small lymphoblasts + child 2-5 years + fever + bone pain + pancytopenia. Diagnosis? B-cell ALL. Immunophenotype? TdT+, CD10+, CD19+, CD22+, MPO−. Best-prognosis cytogenetics? Hyperdiploidy or ETV6-RUNX1 t(12;21). Worst? BCR-ABL t(9;22) or MLL/KMT2A rearrangement.

Pattern 4 — The ITP question: Smear shows isolated thrombocytopenia with megathrombocytes + normal Hb and WBC + post-viral young patient + no hepatosplenomegaly. Diagnosis? Immune thrombocytopenia (ITP). Bone marrow shows? Increased megakaryocytes. First-line treatment if platelets under 30,000 or bleeding? Prednisolone 1 mg/kg/day.

Pattern 5 — The HUS question: Smear shows schistocytes + thrombocytopenia + child with bloody diarrhoea + AKI + E. coli O157:H7. Diagnosis? Typical HUS (STEC-HUS). ADAMTS13? Normal. Treatment? Supportive, dialysis if needed, AVOID antibiotics and platelet transfusion routinely.

Pattern 6 — The TTP question: Smear shows schistocytes + thrombocytopenia + adult with neurological symptoms + renal involvement + fever. Diagnosis? Thrombotic thrombocytopenic purpura (TTP). ADAMTS13? Under 10 percent. Treatment? Urgent plasma exchange + steroids + rituximab + caplacizumab.

Pattern 7 — The MAHA differential question: Schistocytes on smear. Differential? TTP, HUS (typical and atypical), DIC, preeclampsia/HELLP, malignant hypertension, mechanical heart valve hemolysis, drug-induced MAHA, AIHA-on-MAHA overlap. Coagulation panel and ADAMTS13 are the discriminators.

High-yield one-liners:

• Faggot cells (bundles of Auer rods) = AML M3 (APL); t(15;17) PML-RARA; ATRA + ATO
• DIC at presentation in 80-90 percent of APL — start ATRA empirically
• Full granulocyte maturation + basophilia + low LAP = CML; t(9;22) BCR-ABL; imatinib
• Three phases of CML: chronic → accelerated → blast crisis
• Lymphoblasts with scant cytoplasm + TdT+ + MPO− + paediatric = B-cell ALL
• ALL: never Auer rods, never MPO positive (the discriminator from AML)
• Megathrombocytes with isolated thrombocytopenia + post-viral + normal Hb/WBC = ITP
• Schistocytes + thrombocytopenia + neurological + ADAMTS13 under 10% = TTP → PLEX
• Schistocytes + thrombocytopenia + bloody diarrhoea + AKI in child = STEC-HUS → supportive
• TTP and HUS have normal coagulation (vs DIC which has prolonged PT/aPTT, low fibrinogen)
• All MAHA: DAT-negative (vs AIHA which is DAT-positive)
• Atypical HUS = complement dysregulation → eculizumab
• Leukoerythroblastic picture (nucleated RBCs + immature WBCs) = marrow infiltration (myelofibrosis, metastases, severe stress)
• Teardrop cells = myelofibrosis

Frequently Asked Questions

How do you systematically approach a peripheral blood smear for NEET PG?

Follow a four-line systematic approach for every smear. (1) Red cells — size (normocytic, microcytic, macrocytic), shape (spherocyte, schistocyte, target cell, sickle cell, teardrop, elliptocyte), inclusions (Howell-Jolly, basophilic stippling, Pappenheimer, Heinz, parasites), and arrangement (rouleaux, agglutination). (2) White cells — total count estimate, predominant lineage, blasts present or not (and which type — myeloid vs lymphoid), maturation pattern, dysplasia, granulocyte morphology (Pelger-Huet, hypersegmentation, toxic granules, Dohle bodies, Auer rods). (3) Platelets — adequate, decreased, increased; morphology (megathrombocytes, hypogranular). (4) Special findings — leukoerythroblastic picture (nucleated RBCs + immature WBCs together — indicates marrow infiltration or severe stress), parasites, microorganisms. Then integrate with clinical history and labs.

What is the difference between Auer rods and faggot cells in AML?

Auer rods are needle-shaped pink-purple cytoplasmic inclusions composed of fused azurophilic granules, seen in the cytoplasm of myeloblasts in acute myeloid leukaemia. They are pathognomonic for AML (helping distinguish from ALL, where they are never seen). Faggot cells are myeloblasts or promyelocytes containing bundles of multiple Auer rods stacked together resembling a bundle of sticks (faggot). Faggot cells are particularly characteristic of acute promyelocytic leukaemia (AML M3), which has the t(15;17) PML-RARA translocation. M3 is the FAB subtype that responds to all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) and is the only AML subtype where DIC at diagnosis is so common that ATRA is started empirically before cytogenetic confirmation.

How do you differentiate ALL from AML on peripheral smear?

Both produce circulating blasts but with distinct morphology and cytochemistry. ALL lymphoblasts are typically smaller, with scant cytoplasm, condensed nuclear chromatin, indistinct nucleoli, NO Auer rods, NO granules. They are TdT-positive on immunohistochemistry, PAS-positive in block pattern (for B-ALL), and myeloperoxidase (MPO) negative. AML myeloblasts are typically larger, with more abundant cytoplasm, fine chromatin, prominent nucleoli, may have Auer rods (M1, M2, M3), may have granules. They are MPO-positive, Sudan black positive, non-specific esterase positive in monocytic subtypes (M4, M5), and TdT negative. Flow cytometry definitively distinguishes — ALL is CD19, CD22, CD79a, TdT positive for B-ALL; CD2, CD3, CD7 for T-ALL. AML is CD13, CD33, CD117, MPO positive. ALL is the commonest paediatric leukaemia (peak age 2-5); AML is commoner in older adults.

What are megathrombocytes and when do they appear on peripheral smear?

Megathrombocytes (also called giant platelets) are platelets larger than a red blood cell — normal platelets are 2-3 micrometres in diameter while megathrombocytes are over 4 micrometres. They reflect increased platelet turnover with release of immature, large platelets from the bone marrow. They appear in (1) immune thrombocytopenia (ITP) — peripheral destruction with compensatory megakaryocyte hyperplasia and release of large young platelets; (2) myeloproliferative disorders (essential thrombocythemia, polycythemia vera, primary myelofibrosis); (3) inherited macrothrombocytopenias (Bernard-Soulier syndrome — giant platelets with absent GP Ib/IX/V, May-Hegglin anomaly — giant platelets with Dohle-like inclusions in neutrophils, MYH9-related disorders, Wiskott-Aldrich syndrome which paradoxically has SMALL platelets); (4) recovery from chemotherapy or thrombocytopenia. Megathrombocytes with thrombocytopenia and otherwise normal smear in an otherwise well child or young adult suggest ITP.

What is the role of schistocytes in microangiopathic hemolytic anaemia (MAHA)?

Schistocytes (also called helmet cells, fragmented red cells) are red-cell fragments produced by mechanical shearing through fibrin strands in small vessels. They are the morphological hallmark of microangiopathic hemolytic anaemia (MAHA) and require over 1 percent of red cells fragmented on smear to be considered diagnostic. The differential of MAHA on smear is: (1) thrombotic thrombocytopenic purpura (TTP) — ADAMTS13 deficiency (under 10 percent activity), classic pentad of MAHA + thrombocytopenia + neurological symptoms + renal involvement + fever (full pentad is rare; MAHA + thrombocytopenia alone should trigger urgent plasma exchange); (2) hemolytic uraemic syndrome (HUS) — typically post-diarrhoeal in children with Shiga-toxin E. coli O157:H7 (typical HUS) or atypical HUS from complement dysregulation, dominant renal failure; (3) DIC — sepsis or obstetric causes, prolonged PT/aPTT, low fibrinogen, raised D-dimer (TTP/HUS have normal coagulation); (4) preeclampsia/HELLP; (5) malignant hypertension; (6) mechanical heart valve hemolysis; (7) drug-induced MAHA. Differentiating TTP from HUS and DIC on the smear is impossible — you need ADAMTS13 levels, stool culture, and coagulation panel.

---

Written by: NEETPGAI Editorial Team Reviewed by: Pending SME Review Last reviewed: May 2026